Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection

INTRODUCTION: Asunaprevir (ASV) is a potent, pangenotypic, twice-daily hepatitis C virus (HCV) NS3 inhibitor indicated for the treatment of chronic HCV infection. METHODS: A population pharmacokinetic (PPK) model was developed using pooled ASV concentration data from 1239 HCV-infected subjects who r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Li, Li, Hanbin, Chan, Phyllis, Eley, Timothy, Gandhi, Yash, Bifano, Marc, Osawa, Mayu, Ueno, Takayo, Hughes, Eric, AbuTarif, Malaz, Bertz, Richard, Garimella, Tushar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986681/
https://www.ncbi.nlm.nih.gov/pubmed/29589331
http://dx.doi.org/10.1007/s40121-018-0197-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986681/
https://www.ncbi.nlm.nih.gov/pubmed/29589331
http://dx.doi.org/10.1007/s40121-018-0197-y

Ejemplares similares